Anika Therapeutics, Inc. (ANIK)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Anika Therapeutics, Inc. (ANIK) is up 47.8% since the beginning of the year. At $14 per share, ANIK is trading 12.6% below its 52-week high of $16. Investors who bought $1,000 worth of ANIK shares 5 years ago would now be looking at an investment worth $326.

Anika Therapeutics, Inc. (ANIK) has returned 47.76% so far this year and 34.09% over the past 12 months. Over the last ten years, ANIK has returned -12.02% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since May 4, 1993, ANIK's average daily return is +0.11%, while the average monthly return is +1.76%. At this rate, an investment would double in approximately 3.3 years.

Historically, 50% of months were positive and 50% were negative. The best month was Dec 1993 with a return of +88.2%, while the worst month was May 2000 at -67.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.

On a daily basis, ANIK closed higher 46% of trading days. The best single day was Dec 29, 1993 with a return of +41.7%, while the worst single day was May 31, 2000 at -65.5%.

Anika Therapeutics, Inc. has an annualized alpha of 24.66%, beta of 0.59, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since May 04, 1993.

• This stock participated in 140.62% of S&P 500 Index downside but only 126.12% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.59 may look defensive, but with R2 of 0.03 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ANIK ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Anika Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Anika Therapeutics, Inc. was 95.88%, occurring on Dec 26, 2000. Recovery took 1651 trading sessions.

The current Anika Therapeutics, Inc. drawdown is 80.64%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Anika Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Anika Therapeutics, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.